Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2010 by Sun Yat-sen University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Sun Yat-sen University

ClinicalTrials.gov Identifier:

NCT01256125

First received: December 7, 2010

Last updated: NA

Last verified: October 2010

History: No changes posted

Tracking Information
First Received Date ^ICMJE	December 7, 2010
Last Updated Date	December 7, 2010
Start Date ^ICMJE	October 2010
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE (submitted: December 7, 2010)	Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein. [ Time Frame: 1-8 weeks after transplantation ] [ Designated as safety issue: Yes ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE (submitted: December 7, 2010)	Long-term follow-up of Allogene MSCs transplantation through peripheral vein. [ Time Frame: 3-60 months ] [ Designated as safety issue: Yes ]
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
Official Title ^ICMJE	Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
Brief Summary	Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case Control Time Perspective: Retrospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Probability Sample
Study Population	Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.
Condition ^ICMJE	Allogene MSCs Transplantation Chronic Liver Diseases Patients Peripheral Vein
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Allogene MSCs transplantation Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments. control only medical treatments were performed in patients with chronic liver diseases.
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Recruiting
Estimated Enrollment ^ICMJE	60
Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease. age: 15-65 years old. Exclusion Criteria: pregnant women and women in lactation. other systems and organs disfunction space-occupying lesion were found in liver. concurrent infection with HIV and other immunodeficiency diseases. DIC and active bleeding were confirmed.
Gender	Both
Ages	15 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	China

Administrative Information
NCT Number ^ICMJE	NCT01256125
Other Study ID Numbers ^ICMJE	SunYat-sen U 11-5-1
Has Data Monitoring Committee	Yes
Responsible Party	Zhi-liang Gao, 3rd Affiliated Hospital of Sun Yat-sen University
Study Sponsor ^ICMJE	Sun Yat-sen University
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Sun Yat-sen University
Verification Date	October 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top